REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Announces Commencement of Public Offering of Common Stock

19 Jul 2022 16:01:00 By Nasdaq GlobeNewswire

Revolution Medicines Appoints Lorence Kim, M.D., Accomplished Health Care Industry Leader, to Board of Directors

13 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236

28 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

09 Jun 2022 16:02:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress

09 May 2022 16:02:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022

21 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022

09 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference

01 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

28 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022

22 Feb 2022 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

03 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

11 Jan 2022 14:15:00 By Nasdaq GlobeNewswire

Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

24 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

10 Nov 2021 16:05:01 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

08 Nov 2021 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021

03 Nov 2021 16:05:00 By Nasdaq GlobeNewswire

Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

30 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

15 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 16:05:00 By Nasdaq GlobeNewswire